Literature DB >> 16307453

Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants.

Tomoe Fujita1, Thomas J Urban, Maya K Leabman, Kazumi Fujita, Kathleen M Giacomini.   

Abstract

The human organic cation transporter 2 (OCT2, SLC22A2) is a multispecific transporter of organic cations, including many clinically used drugs. OCT2 is primarily responsible for the uptake of organic cations across the basolateral membrane of renal tubular epithelial cells and is considered a major transporter in the active secretion of organic cations in the kidney. Uptake of organic cations by OCT2 is driven by the inside-negative membrane potential and is pH-sensitive. Regulation of OCT2 at the transcriptional level by steroid hormones and at the protein level by various protein kinases has been described. Several human genetic variants in the coding region of OCT2 have been identified and functionally characterized, including both polymorphic and rare variants. A variety of structurally diverse compounds have been shown to interact with OCT2, including endogenous compounds, drugs, and dietary supplements.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16307453     DOI: 10.1002/jps.20536

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  33 in total

1.  Genetic polymorphisms of the organic cation transporter 1 gene (SLC22A1) within the Cape Admixed population of South Africa.

Authors:  Morne Du Plessis; Brendon Pearce; Clifford Jacobs; Nisreen Hoosain; Mongi Benjeddou
Journal:  Mol Biol Rep       Date:  2014-11-15       Impact factor: 2.316

2.  Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.

Authors:  Shiro Itagaki; Vadivel Ganapathy; Horace T B Ho; Mingyan Zhou; Ellappan Babu; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2012-03-06       Impact factor: 3.922

Review 3.  Considerations when prescribing trimethoprim-sulfamethoxazole.

Authors:  Joanne M-W Ho; David N Juurlink
Journal:  CMAJ       Date:  2011-10-11       Impact factor: 8.262

4.  A common 5'-UTR variant in MATE2-K is associated with poor response to metformin.

Authors:  J H Choi; S W Yee; A H Ramirez; K M Morrissey; G H Jang; P J Joski; J A Mefford; S E Hesselson; A Schlessinger; G Jenkins; R A Castro; S J Johns; D Stryke; A Sali; T E Ferrin; J S Witte; P-Y Kwok; D M Roden; R A Wilke; C A McCarty; R L Davis; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2011-09-28       Impact factor: 6.875

Review 5.  The pharmacology of novel oral anticoagulants.

Authors:  Tracy A DeWald; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

6.  Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter.

Authors:  Horace T B Ho; Yongmei Pan; Zhiyi Cui; Haichuan Duan; Peter W Swaan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-08-04       Impact factor: 4.030

Review 7.  Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney.

Authors:  Hideyuki Motohashi; Ken-ichi Inui
Journal:  AAPS J       Date:  2013-02-22       Impact factor: 4.009

8.  Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).

Authors:  Anne T Nies; Elke Herrmann; Manuela Brom; Dietrich Keppler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

9.  Pharmacogenetics of Anti-Diabetes Drugs.

Authors:  Johanna K Distefano; Richard M Watanabe
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-01

10.  Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.

Authors:  K K Filipski; R H Mathijssen; T S Mikkelsen; A H Schinkel; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2009-07-22       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.